Emergent BioSolutions Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases

Published: Apr 11, 2013

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has presented data on ES210, one of its bispecific ADAPTIRTM (Modular Protein Technology) molecules, that is targeting autoimmune disease at Keystone Symposia’s Advances in the Knowledge and Treatment of Autoimmunity in Whistler, British Columbia, Canada. The ES210 molecule was engineered using Emergent’s ADAPTIR technology platform and contains binding sites specific for CD86 coupled to a monomeric form of IL-10 known to confer immunosuppressive activity.

Back to news